Amsterdam, The Netherlands, October 19, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it has raised gross proceeds of €31.2 million through a private placement of 3.9 million new shares to institutional investors via an accelerated bookbuilding process as announced on October 18, 2018 (the “Placing”). The Placing was completed at a subscription price of €8.00 per share and represented approximately 19% of the issued share capital of the Company prior to the transaction. The new ordinary shares will rank pari passu in all respects with the currently outstanding shares of the Company and are expected to be listed and traded on Euronext Amsterdam and Euronext Brussels on October 23, 2018. Following the Placing, the issued share capital of the Company will consist of 24,341,410 ordinary shares.
Arthur Lahr, CEO of Kiadis Pharma, commented: “Today’s oversubscribed private placement shows investors’ commitment and trust in Kiadis Pharma’s progress and potential. I’m delighted to welcome several new global specialist healthcare investors to our share register. With the €31.2 million raised in this offering and if we draw the existing €15m debt facility upon a positive CHMP opinion, we would have sufficient funds into the second half of 2020.”
Kiadis Pharma intends to use the net proceeds of the Placing to:
– Continue the Phase 3 international, randomized, controlled, multi-centre clinical trial for ATIR101 in the United States, Canada and Europe;
– Further prepare for commercialization in Europe by investing into market access preparation, reimbursement, commercial organization and commercial manufacturing;
– Apply funds for general corporate purposes and other working capital needs.
Jefferies International Limited (“Jefferies”) acted as Global Coordinator. Jefferies and Kempen & Co N.V. acted as Joint Bookrunners and KBC Securities N.V. and Oppenheimer & Co. Inc. acted as Co-Managers in connection with the Placing. Saola Healthcare Partners acted as financial advisor to the Company.
